John M. Kane, MD: When someone first develops a schizophrenia illness, I think one of our biggest challenges is helping that person to prevent the recurrence of a psychotic episode. Someone who ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that ...

Relapses can have devastating consequences for people with mental disorders such as schizophrenia, bipolar disorder, depression, or an anxiety disorder. After every relapse, it may become increasingly ...

Please provide your email address to receive an email when new articles are posted on . Clozapine and second-generation long-acting formulations of certain antipsychotics decreased risk for ...

A large meta-analysis sheds light on the best antipsychotic maintenance strategy to prevent relapse in clinically-stable schizophrenia — with some unexpected results that have potential implications ...

Risk of isolated central nervous system (CNS) involvement was found to be significantly lower in patients with diffuse large B-cell lymphoma who received high-dose methotrexate vs RCHOP chemotherapy, ...

Major depressive disorder or what is more commonly known as clinical depression is a significant condition that can impact many aspects of people’s lives. It causes prolonged and persistent symptoms ...

Medical University of South Carolina scientists report in Neuron that they have uncovered a way to restore an opioid-weakened brain pathway in a preclinical model. With funding from the National ...

BOSTON, Mass. (Ivanhoe Newswire) - CAR T-cell therapy has revolutionized the treatment of certain blood cancers — including leukemias, lymphomas and multiple myeloma. CAR T-cells are genetically ...

Thalidomide demonstrated superior efficacy in preventing the relapse of immunoglobulin G4–related disease (IgG4-RD) during a 12-month follow-up period in a placebo-controlled trial. The treatment ...